ETON Stock Analysis: Eton Pharmaceuticals | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 1.034m USD | 12M Return: 156.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 13.4M
Qual. Beats: -1
Rev. Trend: 94.2%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 7.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is a U.S.-based pharmaceutical company headquartered in Deer Park, Illinois, that develops and commercializes treatments for rare diseases. The company was incorporated in 2017 and went public in November 2018.
Its commercial portfolio includes Increlex (severe primary IGF-1 deficiency), Alkindi Sprinkle and Khindivi (adrenal insufficiency), Galzin (Wilson disease), PKU Golike (phenylketonuria), Carglumic Acid (N-acetylglutamate synthase deficiency), Betaine Anhydrous (homocystinuria), and Nitisinone (tyrosinemia type 1). Several of these products were acquired or in-licensed rather than discovered in-house, which is a common approach in the rare disease space where small patient populations make in-licensing and niche commercialization more efficient than large-scale R&D.
Etons late-stage pipeline includes ET-600 (diabetes insipidus), Amglidia (neonatal diabetes mellitus), ET-700 (Wilson disease), ET-800 (adrenal insufficiency), and the ZENEO hydrocortisone autoinjector (adrenal crisis). Because rare disease therapeutics typically benefit from orphan drug designation, the company can pursue expedited regulatory pathways and extended market exclusivity, supporting a specialty business model focused on small patient populations with limited treatment options.
- Rare disease product revenue scales with Increlex and Alkindi adoption
- Late-stage pipeline approvals for ET-600 Amglidia ZENEO autoinjector drive upside
- Reimbursement and pricing pressure on rare disease therapeutics compresses margins
| Net Income: -1.48m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA 9.22 > 1.0 |
| NWC/Revenue: 10.43% < 20% (prev 50.92%; Δ -40.50% < -1%) |
| CFO/TA 0.16 > 3% & CFO 15.8m > Net Income -1.48m |
| Net Debt (11.5m) to EBITDA (5.45m): 2.11 < 3 |
| Current Ratio: 1.21 > 1.5 & < 3 |
| Outstanding Shares: last quarter (31.5m) vs 12m ago 17.34% < -2% |
| Gross Margin: 54.77% > 18% (prev 58.49%; Δ -3.72% > 0.5%) |
| Asset Turnover: 95.67% > 50% (prev 57.51%; Δ 38.16% > 0%) |
| Interest Coverage Ratio: 0.29 > 6 (EBIT TTM 1.29m / Interest Expense TTM 4.46m) |
| A: 0.09 (Total Current Assets 53.2m - Total Current Liabilities 44.2m) / Total Assets 97.7m |
| B: -1.14 (Retained Earnings -110.9m / Total Assets 97.7m) |
| C: 0.01 (EBIT TTM 1.29m / Avg Total Assets 90.9m) |
| D: 0.46 (Book Value of Equity 30.6m / Total Liabilities 67.1m) |
| Altman-Z'' = -2.52 = D |
| DSRI: 0.45 (Receivables 13.4m/16.4m, Revenue 86.9m/48.3m) |
| GMI: 1.07 (GM 58.49% / 54.77%) |
| AQI: 1.11 (AQ_t 0.45 / AQ_t-1 0.40) |
| SGI: 1.80 (Revenue 86.9m / 48.3m) |
| TATA: -0.18 (NI -1.48m - CFO 15.8m) / TA 97.7m) |
| Beneish M = -2.79 (Cap -4..+1) = A |
As of July 14, 2026, the stock is trading at USD 37.34 with a total of 265,254 shares traded. Over the past week, the price has changed by -1.79%, over one month by +16.14%, over three months by +43.34% and over the past year by +156.81%.
Current recommended Stop Loss: 35.40 (which is 5.2% or 1.2 ATR below the current price).
Eton Pharmaceuticals has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy ETON.
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 45.7 | 22.3% |
P/E Forward = 55.2486
P/S = 11.8916
P/B = 33.5347
Revenue TTM = 86.9m USD
EBIT TTM = 1.29m USD
EBITDA TTM = 5.45m USD
Long Term Debt = 18.9m USD (from longTermDebt, last quarter)
Short Term Debt = 11.8m USD (from shortTermDebt, last quarter)
Debt = 31.2m USD (corrected: LT Debt 18.9m + ST Debt 11.8m) + Leases 440k
Net Debt = 11.5m USD (calculated: Debt 31.2m - CCE 19.7m)
Enterprise Value = 1.05b USD (1.03b + Debt 31.2m - CCE 19.7m)
Interest Coverage Ratio = 0.29 (Ebit TTM 1.29m / Interest Expense TTM 4.46m)
EV/FCF = 67.74x (Enterprise Value 1.05b / FCF TTM 15.4m)
FCF Yield = 1.48% (FCF TTM 15.4m / Enterprise Value 1.05b)
FCF Margin = 17.75% (FCF TTM 15.4m / Revenue TTM 86.9m)
Net Margin = -1.70% (Net Income TTM -1.48m / Revenue TTM 86.9m)
Gross Margin = 54.77% ((Revenue TTM 86.9m - Cost of Revenue TTM 39.3m) / Revenue TTM)
Gross Margin QoQ = 60.72% (prev 61.56%)
Tobins Q-Ratio = 10.70 (Enterprise Value 1.05b / Total Assets 97.7m)
Interest Expense / Debt = 14.29% (Interest Expense 4.46m / Debt 31.2m)
Taxrate = 1.27% (20.0k / 1.57m)
NOPAT = 1.28m (EBIT 1.29m * (1 - 1.27%))
Current Ratio = 1.21 (Total Current Assets 53.2m / Total Current Liabilities 44.2m)
Debt / Equity = 1.02 (Debt 31.2m / totalStockholderEquity, last quarter 30.6m)
Debt / EBITDA = 2.11 (Net Debt 11.5m / EBITDA 5.45m)
Debt / FCF = 0.75 (Net Debt 11.5m / FCF TTM 15.4m)
Total Stockholder Equity = 26.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.62% (Net Income -1.48m / Total Assets 97.7m)
RoE = -5.68% (Net Income TTM -1.48m / Total Stockholder Equity 26.0m)
RoCE = 2.88% (EBIT 1.29m / Capital Employed (Equity 26.0m + L.T.Debt 18.9m))
RoIC = 2.09% (NOPAT 1.28m / Invested Capital 61.0m)
WACC = 8.31% (E(1.03b)/V(1.06b) * Re(8.14%) + D(31.2m)/V(1.06b) * Rd(14.29%) * (1-Tc(0.01)))
Discount Rate = 8.14% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 72.73 | Cagr: 9.46%
[DCF] Terminal Value 77.97% ; FCFF base≈11.5m ; Y1≈13.1m ; Y5≈19.3m
[DCF] Fair Price = 10.21 (EV 291.1m - Net Debt 11.5m = Equity 279.6m / Shares 27.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -2.96 | # QB: -1
Revenue Correlation: 94.20 | Revenue CAGR: 51.55% | SUE: 2.01 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.19 | Chg30d=-5.00% | Revisions=-25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.31 | Chg30d=+34.78% | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=1.01 | Chg30d=+20.24% | Revisions=+25% | GrowthEPS=+215.6% | GrowthRev=+50.7%
EPS next Year (2027-12-31): EPS=1.88 | Chg30d=+20.51% | Revisions=+25% | GrowthEPS=+86.1% | GrowthRev=+51.5%